ReviewReproductive sciences (Thousand Oaks, Calif.)2015
Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.
Review in Reproductive sciences (Thousand Oaks, Calif.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Cardiovascular Changes in Menopause.Current cardiology reviews · 2021Pooled it
- Trial
- Article
- Soluble Receptor for Advanced Glycation End Products and Incident Hypertension in REGARDS.American journal of hypertension · 2025Article
- Exploring the Therapeutic Potential ofCurrent issues in molecular biology · 2025Article
- Association between cardiovascular health and osteoporotic fractures: a national population-based study.Scientific reports · 2025Article
- Diallyl Trisulfide and Cardiovascular Health: Evidence and Potential Molecular Mechanisms.International journal of molecular sciences · 2024Review
- Review
- Associations of ultra-processed food consumption with cardiovascular disease and all-cause mortality: UK Biobank.European journal of public health · 2022Observational
- Impact of Dietary Advanced Glycation End Products on Female Reproduction: Review of Potential Mechanistic Pathways.Nutrients · 2022Review
- Exploring the "gene-protein-metabolite" network of coronary heart disease with phlegm and blood stasis syndrome by integrated multi-omics strategy.Frontiers in pharmacology · 2022Article
- Elevated level of the soluble receptor for advanced glycation end-products involved in sarcopenia: an observational study.BMC geriatrics · 2021Observational
- A review on mechanism of inhibition of advanced glycation end products formation by plant derived polyphenolic compounds.Molecular biology reports · 2021Review
- Mechanisms of Endothelial Dysfunction in Pre-eclampsia and Gestational Diabetes Mellitus: Windows Into Future Cardiometabolic Health?Frontiers in endocrinology · 2020Review
- Soluble Forms of the Receptor for Advanced Glycation Endproducts (RAGE) in Periodontitis.Scientific reports · 2019Article
- Advanced glycation end products alter steroidogenic gene expression by granulosa cells: an effect partially reversible by vitamin D.Molecular human reproduction · 2018Article
- Role of RAGE in Alzheimer's Disease.Cellular and molecular neurobiology · 2016Review
- Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory disease.Vascular pharmacology · 2015Review
- Comet assay as an indirect measure of systemic oxidative stress.Journal of visualized experiments : JoVE · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) represents the most significant cause of death in postmenopausal women. Advanced glycation end products (AGEs) are formed by nonenzymatic modification of proteins, lipids, and nucleic acids by glucose. This review focuses on the contribution of AGEs and their receptors to the development of CVD in menopause. Advanced glycation end products circulate and activate the proinflammatory endothelial cell surface receptor called RAGE, bind to the extracellular matrix of the cardiovascular system, or bind to the circulating anti-inflammatory soluble form of RAGE (sRAGE). Data emerging from human and animal studies suggest that AGEs and both receptors (RAGE and sRAGE) are implicated in the pathophysiology of CVD. Particular emphasis has been given to the role of AGE-RAGE axis in oxidative stress, inflammation, endothelial cell toxicity, and progression of atherosclerosis in menopause. Data accruing from human and animal studies suggest that RAGE expression level and circulating sRAGE level are associated with estradiol and are correlated with CVD risk factors, such as adiposity, dyslipidemia, insulin resistance, diabetes, and metabolic syndrome. By recognizing the impact of AGEs on atherosclerosis, pharmacological strategies targeting the AGE-RAGE pathway hold therapeutic potential for CVD in menopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.